Someone may have a small, painless lump in their arm or leg for months without it hindering their daily life or work, leading them to assume it is just a fatty deposit or the result of an old injury and thus delay seeing a doctor. However, in some cases, that lump could be the first sign of 'sarcoma'—one of the rarest and most diverse types of cancer. Its danger lies not only in its aggressiveness but in the fact that its early symptoms can pass silently, failing to alert the patient or even, sometimes, the doctor during an initial visit.

This reality is what drives scientific societies and patient organizations around the world to dedicate the month of July each year to Sarcoma Awareness Month. The goal is to highlight its early signs, encourage prompt diagnosis, and promote the referral of patients to specialized centers. Accumulated medical expertise confirms that early detection not only increases treatment success rates but can completely alter the course of the disease, often allowing for less complex treatments that better preserve organ function, according to the latest guidelines from the European Society for Medical Oncology (ESMO) and the U.S. National Comprehensive Cancer Network (NCCN). Perhaps most concerning is that many sarcoma patients reach specialized centers months after symptoms first appear because they never imagined a small, painless lump could be a malignant tumor.

Two Main Types and Distinct Characteristics

Although sarcoma accounts for less than one percent of adult cancers, it includes over 100 subtypes, each differing in biological behavior and response to treatment. Sarcoma originates in the body’s supportive tissues, such as muscles, fat, tendons, ligaments, blood vessels, nerves, bones, and cartilage. This vast diversity makes it one of the most complex groups of tumors to diagnose and treat; managing this group now relies on multidisciplinary medical teams and molecular diagnostic techniques that have become the cornerstone of selecting the appropriate treatment for each patient.

Doctors divide sarcoma into two main groups:

1. Soft tissue sarcoma, which is the most common type in adults and can appear anywhere in the body, particularly the limbs. It is projected that in 2026, about 13,910 cases of soft tissue sarcoma will be recorded in the United States, with a five-year survival rate of approximately 65.7 percent.

2. Bone sarcoma, which affects the bone tissue itself, with osteosarcoma being the most common type, especially in children and adolescents. It is projected that in 2026, about 4,110 cases will be recorded in America, with a five-year survival rate of approximately 68.7 percent.

This disease is often misdiagnosed or diagnosed late due to its rarity and similarity to other types of cancer, according to reports from the American Association for Cancer Research (AACR).

Despite the rarity of these tumors, they represent a higher proportion of solid tumors in children compared to adults, which explains the significant attention given to them in pediatric oncology.

The problem is that sarcomas do not announce themselves in their early stages. In many cases, they cause no pain and do not affect the patient's general health, manifesting only as a slowly growing lump or intermittent local pain that may persist for weeks or months before the patient decides to see a doctor.

For this reason, modern guidelines from the European Society for Medical Oncology and the U.S. National Comprehensive Cancer Network emphasize the necessity of not ignoring any lump that grows gradually, exceeds five centimeters in diameter, is located deep within tissues, is accompanied by persistent pain, or recurs after being surgically removed. These signs do not necessarily indicate cancer, but they require expert evaluation because early diagnosis remains the most influential factor in treatment success and the reduction of complications.

This is not limited to soft tissue tumors; in bone sarcoma, the first symptom may be pain that increases over time and becomes more pronounced at night or during physical activity. It may be accompanied by swelling or even a fracture occurring after a minor injury due to bone weakness. Here lies the importance of not simply dismissing pain as 'growing pains' or the result of athletic strain, especially if it persists or worsens, as it could be the first indicator of a problem needing precise evaluation.

Causes and Diagnosis

Why does sarcoma occur? This is a question many patients and their families ask. Despite all scientific progress, the direct cause of most sarcoma cases remains unknown. Studies indicate that the majority of patients have no clear risk factor; however, some rare genetic syndromes, such as Li-Fraumeni syndrome and neurofibromatosis type 1, as well as prior exposure to radiation therapy or chronic lymphedema, may increase the risk for specific groups, according to recent reviews published in the journal 'Nature Reviews Clinical Oncology.' Conversely, there is no scientific evidence to prove that sarcoma arises as a result of a direct injury or bruise, which is one of the most common misconceptions among the public.

Because most sarcoma cases cannot be prevented, the best way to improve outcomes is to raise awareness of early signs and accelerate access to specialized centers upon suspicion. Periodic follow-up after treatment is also an essential part of care, aiming to detect any recurrence early, manage potential complications, and help patients regain their physical and psychological well-being to return to their normal lives.

Sarcoma diagnosis depends on three main elements: clinical assessment, medical imaging, and biopsy. Magnetic Resonance Imaging (MRI) is the preferred choice for evaluating most soft tissue tumors because it provides accurate information about the tumor's size, boundaries, and relationship to surrounding tissues. Computed Tomography (CT) is used in other cases, especially to evaluate the lungs, which are the most common site of metastasis for some types of sarcoma. Confirmation of the diagnosis is only possible through a biopsy, which should be performed at the center that will handle the patient's treatment, or in coordination with them, because the site and method of sampling can influence the future surgical plan, as international guidelines repeatedly emphasize.

With the development of molecular pathology, sarcoma diagnosis no longer relies on traditional microscopic examination alone. It now includes immunological and molecular analyses that help identify the tumor subtype with greater accuracy and detect mutations or genetic fusions that may play a role in treatment selection. This evolution has contributed to the reclassification of several types of sarcoma and has become one of the most important shifts in oncology in recent years, according to the World Health Organization's classification of tumors.